Universal reference book for medicines
Product name: TAZAN (TAZAN)

Active substance: chondroitin sulfate sodium, glucosamine

Type: A drug stimulating the process of cartilage tissue regeneration

Manufacturer: MS-VITA (Russia) produced SYNTHESIS (Russia)
Composition, form of production and packaging
?
Tablets covered with a film coat from white to almost white, biconvex, oval, rough surface is allowed.
1 tab.

chondroitin sodium sulfate 500 mg

glucosamine hydrochloride 500 mg

[PRING] silicon dioxide colloid (aerosil) 8.5 mg, calcium stearate 17 mg, talc 51 mg, crospovidone 170 mg, povidone low molecular weight 86 mg, potato starch 4.5 mg, ludipress to obtain a core mass of 1700 mg.

Sheath composition: hypromellose 27.2 mg, propylene glycol 2.5 mg, macrogol 23.8 mg, titanium dioxide 16.5 mg.

5 pieces.
- packings cellular planimetric (6) - packs cardboard.
5 pieces.
- packings cellular planimetric (12) - packs cardboard.
5 pieces.
- packings cellular outline (18) - packs cardboard.
30 pcs.
- polymer cans (1) - packs of cardboard.
60 pcs.
- polymer cans (1) - packs of cardboard.
90 pcs.
- polymer cans (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2013.

PHARMACHOLOGIC EFFECT

Stimulates the regeneration of cartilaginous tissue.
Glucosamine and chondroitin sulfate are involved in the synthesis of connective tissue, helping to prevent cartilage destruction processes and stimulating tissue regeneration. The introduction of exogenous glucosamine enhances the production of the cartilage matrix and provides non-specific protection against chemical damage to the cartilage. Glucosamine in the form of a sulfate salt is a precursor of hexosamine, and the sulfate anion is necessary for the synthesis of glycosaminoglycans. Another possible function of glucosamine is to protect the damaged cartilage from metabolic destruction caused by non-steroidal anti-inflammatory drugs and glucocorticosteroid, as well as its own moderate anti-inflammatory effect.
Chondroitin sulfate, regardless of whether it is absorbed in an intact form or as separate components, serves as an additional substrate for the formation of a healthy cartilage matrix.
Stimulates the formation of hyaluronone, the synthesis of proteoglycans and collagen type II, and also protects hyaluronone from enzymatic cleavage (by suppressing the activity of hyaluronidase) and the damaging effect of free radicals; maintains the viscosity of the synovial fluid, stimulates mechanisms of cartilage repair. In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for non-steroidal anti-inflammatory drugs.
PHARMACOKINETICS

Glucosamine: bioavailability with oral intake - 25% (effect of "first passage" through the liver).

Distributed in tissues: the highest concentrations are found in the liver, kidneys and articular cartilage.
About 30% of the dose is persistently persistent in bone and muscle tissue. It is excreted mainly by the kidneys in unchanged form; partially - the intestine. T 1/2 - 68 h.
Chondroitin sulfate: once taken at a dose of 0.8 g (or 2 times / day in a dose of 0.4 g), the concentration in the plasma increases for 24 hours. Absolute bioavailability is 12%.
About 10 and 20% of the dose received is absorbed in the form of high molecular weight and low molecular weight derivatives, respectively. The apparent V dis about 0.44 ml / g. It is metabolized by desulfurization. It is excreted by the kidneys. T 1/2 - 310 min.
INDICATIONS

Osteoarthrosis I-III st.

DOSING MODE

Inside.
Adults and children 15 years and older 1 tablet 2 times / day for the first three weeks; 1 tablet 1 time / day for the following weeks and months. Steady therapeutic effect is achieved when taking the drug for at least 6 months.
SIDE EFFECT

Violation of the function of the gastrointestinal tract (pain in epigastrium, flatulence, diarrhea or constipation), dizziness, skin allergic reactions, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia, allergic reactions.

CONTRAINDICATIONS

hypersensitivity to the components of the drug;

- children's age till 15 years;

- marked renal dysfunction.

With caution: bleeding, a tendency to bleeding, diabetes, bronchial asthma.

PREGNANCY AND LACTATION

During pregnancy and during breastfeeding (lactation), the drug is not used.

APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated in marked violation of kidney function.

APPLICATION FOR CHILDREN

Contraindicated in children and adolescents under 15 years.

SPECIAL INSTRUCTIONS

If unwanted effects on the part of the gastrointestinal tract appear, the dose should be reduced 2-fold, and if there is no improvement, cancel the drug.
In the absence of a clinical effect after a treatment course of 4 tablets per day for 4 weeks, the question of clarifying the diagnosis should be resolved.
Impact on the ability to drive vehicles and manage mechanisms

Care must be taken when driving vehicles and engaging in other potentially hazardous activities requiring increased attention and speed of psychomotor reactions.

OVERDOSE

Symptoms: cases of overdose are unknown.

Treatment: gastric lavage, symptomatic therapy.

DRUG INTERACTION

Increases the absorption of tetracyclines, reduces the effect of semisynthetic penicillins and glucosamine.
The drug is compatible with non-steroidal anti-inflammatory drugs and glucocorticosteroid. It is possible to increase the effect of anticoagulants, antiplatelet agents, fibrinolytic agents.
TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of the reach of children, protected from light, at a temperature of no higher than 25 ° C.

Shelf life - 3 years.
Do not use after the expiration date printed on the package.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!